90 likes | 191 Views
Funding Update: Current Situation and Future Prospects. September 18, 2012 Andrea Gay, UNF. MR Initiative Annual Expenditure, 2001-2012. Total expenditure 2001-2012 = $935 million. * Excluding country contributions.
E N D
Funding Update: Current Situation and Future Prospects September 18, 2012 Andrea Gay, UNF
MR Initiative Annual Expenditure, 2001-2012 Total expenditure 2001-2012 = $935 million * Excluding country contributions
Measles & Rubella Initiative Annual Donations 2001-2012 and Financial Resource Requirements, Projections, Funding Gap 2012-2015* 94 59 11 36 38 44 * Excludes all country contributions and direct social mobilization funding from partners
Measles & Rubella Initiative Financial Resource Requirements, Projections, Funding Gap 2013-2015 47 Total Funding Gap 2013-2015: US $96 million 32 18 31 Anticipated Country Contributions Anticipated GAVI Contribution (Rubella) Donor Funds Projected/Pledged/Received Funding Gap (includes PSC)
Resource Requirements by Major Category of Activity, 2013-2015 TotalCost 2013-2015: US $739 million
MR Initiative Donors, 2001-2012 * Includes ARC/UNF and other partners
Where is the Measles & Rubella Initiative Headed? • 2012 measles goals: AFRO (pre-elimination) and WPRO (elimination) • 2013 potential SEARO elimination goal set, begin MR introduction campaigns with GAVI support • 2015GIVS (95% mortality reduction) and MDG 4 goals; measles goal in EMRO and EURO (elimination); rubella goal in EURO (elimination) • 2020goal in AFRO (elimination) • Expand rubella introduction where appropriate; set goals Critical Elements for Success • Political leadership • Timely funding (donor and national governments) • Adequate time for planning and social mobilization • Well performing surveillance
Measles and rubella elimination goalsby WHO Region, March 2012 2015 2015 2000 2010 2015 2012 2020 Pre-elim. (98%) 2012 SEAR: 95% Measles Mortality Reduction by 2015 Elimination 2020? Americas, Europe, E. Mediterranean, W. Pacific, Africa have measles elimination goals Americas and Europe have rubella elimination goals
Considerations for Reorganizing Aspects of MR Initiative Operations • Measles eradication investment case (EIC): research, costing options • Strategic funding for regional elimination goals • Strategic support for non-GAVI eligible countries • Increased surveillance costs (including lab, coverage surveys) • Increased communications costs • Increased training costs for SIAs • Type of MR Initiative involvement (ex: T.A.) in GAVI funded MR intro SIAs or GAVI funded measles SIAs in 6 large countries • Outbreak response fund • Routine immunization • Scale up of MCV1 • Increase MCV2 introduction • Rubella & CRS (MR) • Follow-up campaigns